Cashu FinanceCashu Finance
  • Terminal
  • Spotlight
  • Cashu Research
Log inSign Up
← Back to Terminal
  1. Stocks
  2. Healthcare
  3. NASDAQ
  4. MBIO

Market Cap: $2.41M

MI

Mustang Bio, Inc.

MBIO
NASDAQUSD
Purchase MBIO
OverviewNewsAnalyst ReportsFinancialsPolitician TradesInsider TradesExecutive
Cashu FinanceCashu Finance

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

StocksAboutAdvertisersBrokersContact

Legal

Terms of ServicePrivacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Research is part of Cashu Technology Pty Ltd, which is an authorised representative (AR # 001318029) of Adviser Solutions Group Pty Ltd (ABN 88 601 875 521) (AFSL 485946) (ASG).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by Cashu Technologies Pty Ltd, any of their related body corporates or any other person. To the maximum extent possible, Cashu Technologies Pty Ltd, their related body corporates or any other person do not accept any liability for any statement in this material.

$0.3601
-$0.0099(-2.68%)
At close: Oct 27, 03:09 EDT

Recently from Cashu

Mustang Bio: Leading Genetic Therapy Innovations for Rare Diseases and Cancer Treatments

Mustang Bio: Pioneering Advances in Genetic Therapies for Rare Diseases Mustang Bio, a biopharmaceutical company focused on developing innovative gene therapies, is making significant strides in addre…

Cashu Finance·9 months ago

Mustang Bio: Request for Content to Summarize

I'm sorry, but it seems there is no content provided for me to summarize. Please provide the text or information regarding Mustang Bio or any relevant details, and I will be glad to assist you in crea…

Cashu Finance·10 months ago

Mustang Bio Advances Gene Therapy with Promising MB-106 Clinical Trial Results

Mustang Bio Advances in Gene Therapy with Promising Clinical Trials Mustang Bio, a clinical-stage biopharmaceutical company focused on innovative cell and gene therapies, makes significant strides in…

Cashu Finance·over 1 year ago

Mustang Bio's MB-101 Receives FDA Orphan Drug Designation for Glioblastoma Therapy

Mustang Bio Gains FDA Support for Glioblastoma Therapy Mustang Bio Inc. recently receives a significant boost with the FDA granting Orphan Drug Designation to its investigational cell therapy candidat…

Cashu Finance·over 1 year ago

Open

$0.6836

Prev. Close

$0.37

High

$0.735

Low

$0.6836

Company Profile

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

CEOManuel Litchman
SectorHealthcare
IndustryBiotechnology
Employees4
IPO DateAug 22, 2017
ExchangeNASDAQ
Exchange NameNASDAQ
CurrencyUSD
Headquarters & Contact
Address95 Sawyer Road
City / State / ZIPWaltham, MA, 02453
CountryUnited States
Phone781 652 4500
Websitehttps://www.mustangbio.com